GlassScriptPhysician profile
Anna W Parlin
NPI 1780942722
$14,610.45
in general payments reported to CMS, 2019-2025
30 companies · $2,415 in 2025
The $2,415 reported for 2025 was more than what 84% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,306 · 2020: $185 · 2021: $332 · 2022: $2,488 · 2023: $3,703 · 2024: $2,182 · 2025: $2,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,666 · Consulting Fee: $2,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,665.82 |
| Consulting Fee | $2,633.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $4,238.26 | 2019-2025 | Susvimo, Vabysmo |
| Genentech USA, INC. | $1,655.58 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Sight Sciences, INC. | $1,549.60 | 2021-2025 | Omni Surgical System |
| Alimera Sciences, INC. | $1,143.30 | 2019-2023 | Iluvien |
| Regeneron Healthcare Solutions, INC. | $1,082.74 | 2020-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $809.38 | 2023-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $618.14 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Alcon Vision LLC | $615.54 | 2019-2024 | Rocklatan, Rhopressa, Simbrinza |
| Novartis Pharmaceuticals Corporation | $375.32 | 2019-2020 | |
| Abbvie INC. | $316.44 | 2023-2025 | |
| Amgen INC. | $284.27 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $270.84 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $192.42 | 2024-2025 | Eylea Hd, Eylea |
| Eyepoint US, INC. | $166.79 | 2021-2023 | |
| Eyevance Pharmaceuticals LLC | $155.42 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $144.98 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $133.59 | 2019 | |
| Sun Pharmaceutical Industries INC. | $131.64 | 2019-2023 | Cequa, Xelpros, Bromsite |
| Aerie Pharmaceuticals, INC. | $120.07 | 2019 | |
| Rxsight INC | $119.56 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Astellas Pharma US INC | $109.56 | 2019-2025 | Izervay |
| Hoffmann-La Roche Limited | $81.20 | 2019 | |
| Horizon Therapeutics Plc | $78.53 | 2023 | Tepezza |
| Allergan, INC. | $65.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $45.98 | 2019 | |
| Harrow Eye, LLC | $36.79 | 2025 | Iheezo |
| Biogen, INC. | $30.44 | 2022 | |
| Astellas Pharma Global Development | $19.67 | 2025 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Parlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.